US2016068559A1PendingUtilityA1
Modulators of Histone Methyltransferase, and Methods of Use Thereof
Est. expiryDec 3, 2030(~4.3 yrs left)· nominal 20-yr term from priority
C07H 19/167A61P 35/00C07H 19/16C07D 473/34
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.
Claims
exact text as granted — not AI-modified1 - 99 . (canceled)
100 . A compound of formula II:
or a pharmaceutically acceptable salt, hydrate, enantiomer or stereoisomer thereof, wherein independently for each occurrence,
X is
R 1 is hydrogen, alkyl, cycloalkyl, alkylcycloalkyl, alkylaryl, haloalkyl, formyl, heterocyclyl, heterocyclylalkyl,
or (C 2 -C 4 )alkyl substituted with
R 10 is hydrogen or alkyl;
R 11a is hydrogen, alkyl, or alkyl-cycloalkyl;
R 11b is hydrogen or alkyl; or taken together with R 11a and the nitrogen to which it is attached forms a 4- to 8-membered heterocyclyl comprising 0 or 1 additional heteroatoms;
R 13 is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl or silyl;
R 14 is hydrogen, alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;
R 15 is alkyl, cycloalkyl or cycloalkylalkyl;
R 20 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl;
A is
R 2 is
Y is —NH—, —N(alkyl)-, —O—, or —CR 6 2 —;
R 22a is aryl, heteroaryl, aralkyl, heteroaralkyl, fused bicyclyl, biaryl, aryloxyaryl, heteroaryloxyaryl, aryloxyheteroaryl or heteroaryloxyheteroaryl, each of which is unsubstituted or substituted;
R 22b is hydrogen or alkyl;
R 24 is hydrogen or alkyl;
R 25a , R 25b , R 25c , R 25d are each independently -M 2 -T 2 , in which M 2 is a bond, SO 2 , SO, S, CO, CO 2 , O, O—C 1 -C 4 alkyl linker, C 1 -C 4 alkyl linker, NH, or N(R t ), R t being C 1 -C 6 alkyl, and T 2 is H, halo, or R S4 , R S4 being C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 8-membered heterocycloalkyl, or 5 to 10-membered heteroaryl, and each of O—C 1 -C 4 alkyl linker, C 1 -C 4 alkyl linker, R t , and R S4 being optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, carboxyl, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 6-membered heterocycloalkyl, and 5 to 6-membered heteroaryl;
Z is hydrogen or
R 5a is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, biaryl, alkenylalkyl, alkynylalkyl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonylaminoalkyl, arylsulfonylaminoalkyl, alkylthioalkyl, aralkylthioalkyl or heteroaralkylthioalkyl; or alkyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of hydroxy, halo, carboxy, alkyoxy, aryloxy, aralkyloxy, nitro, amino, amido, aryl and heteroaryl;
R 5b is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, biaryl, alkenylalkyl, alkynylalkyl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonylaminoalkyl, arylsulfonylaminoalkyl, alkylthioalkyl, aralkylthioalkyl or heteroaralkylthioalkyl; or alkyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of hydroxy, halo, carboxy, alkyoxy, aryloxy, aralkyloxy, nitro, amino, amido, aryl and heteroaryl; or taken together with R 5a and the nitrogen to which it is attached forms a 4- to 8-membered heterocyclyl comprising 0 or 1 additional heteroatoms;
each R 6 independently is hydrogen, alkyl or halo; or two geminal R 6 taken together are ethylene, propylene or butylene;
R 7a is hydrogen, lower alkyl, lower haloalkyl, cyano, halo, lower alkoxy, or C 3 -C 5 cycloalkyl, optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of cyano, lower alkoxy and halo; and
R 7b is hydrogen, lower alkyl, lower haloalkyl, cyano, halo, lower alkoxy, or C 3 -C 5 cycloalkyl, optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of cyano, lower alkoxy and halo.
101 . The compound of claim 100 , wherein X is
102 . The compound of claim 100 , wherein X is
103 . A compound of formula II:
or a pharmaceutically acceptable salt, hydrate, enantiomer or stereoisomer thereof, wherein independently for each occurrence,
X is
R 1 is hydrogen, alkyl, cycloalkyl, alkylcycloalkyl, alkylaryl, haloalkyl, formyl, heterocyclyl, heterocyclylalkyl,
or (C 2 -C 4 )alkyl substituted with
except that when X is
R 1 is not
R 10 is hydrogen or alkyl;
R 11a is hydrogen, alkyl, or alkyl-cycloalkyl;
R 11b is hydrogen or alkyl; or taken together with R 11a and the nitrogen to which it is attached forms a 4- to 8-membered heterocyclyl comprising 0 or 1 additional heteroatoms;
R 13 is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl or silyl;
R 14 is hydrogen, alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;
R 15 is alkyl, cycloalkyl or cycloalkylalkyl;
R 20 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl;
A is
R 2 is
Y is —NH—, —N(alkyl)-, —O—, or —CR 6 2 —;
R 22a is aryl or aralkyl, each of which is unsubstituted or substituted;
R 22b is hydrogen or alkyl;
R 24 is hydrogen or alkyl;
R 25a , R 25b , R 25c , R 25d are each independently -M 2 -T 2 , in which M 2 is a bond, SO 2 , SO, S, CO, CO 2 , O, O—C 1 -C 4 alkyl linker, C 1 -C 4 alkyl linker, NH, or N(R t ), R t being C 1 -C 6 alkyl, and T 2 is H, halo, or R S4 , R S4 being C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 8-membered heterocycloalkyl, or 5 to 10-membered heteroaryl, and each of O—C 1 -C 4 alkyl linker, C 1 -C 4 alkyl linker, R t , and R S4 being optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, carboxyl, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 6-membered heterocycloalkyl, and 5 to 6-membered heteroaryl;
Z is hydrogen or
R 5a is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, biaryl, alkenylalkyl, alkynylalkyl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonylaminoalkyl, arylsulfonylaminoalkyl, alkylthioalkyl, aralkylthioalkyl or heteroaralkylthioalkyl; or alkyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of hydroxy, halo, carboxy, alkyoxy, aryloxy, aralkyloxy, nitro, amino, amido, aryl and heteroaryl;
R 5b is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, biaryl, alkenylalkyl, alkynylalkyl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonylaminoalkyl, arylsulfonylaminoalkyl, alkylthioalkyl, aralkylthioalkyl or heteroaralkylthioalkyl; or alkyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of hydroxy, halo, carboxy, alkyoxy, aryloxy, aralkyloxy, nitro, amino, amido, aryl and heteroaryl;
or taken together with R 5a and the nitrogen to which it is attached forms a 4- to 8-membered heterocyclyl comprising 0 or 1 additional heteroatoms;
each R 6 independently is hydrogen, alkyl or halo; or two geminal R 6 taken together are ethylene, propylene or butylene;
R 7a is hydrogen, lower alkyl, lower haloalkyl, cyano, halo, lower alkoxy, or C 3 -C 5 cycloalkyl, optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of cyano, lower alkoxy and halo; and
R 7b is hydrogen, lower alkyl, lower haloalkyl, cyano, halo, lower alkoxy, or C 3 -C 5 cycloalkyl, optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of cyano, lower alkoxy and halo.
104 . The compound of claim 103 , wherein R 24 is hydrogen or alkyl.
105 . The compound of claim 103 , wherein R 25a is hydrogen, alkyl, —O-alkyl, halogen, trifluoroalkyl, —O-trifluoromethyl, or —SO 2 -trifluoromethyl.
106 . The compound of claim 105 , wherein R 25b is hydrogen, alkyl, halogen, or trifluoroalkyl.
107 . The compound of claim 106 , wherein R 25c is hydrogen, alkyl, or halogen; and R 25d is hydrogen.
108 . The compound of claim 103 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts, hydrates, enantiomers and stereoisomers thereof.
109 . The compound of claim 100 , wherein R 2 is
110 . The compound of claim 109 , wherein Y is —NH—, —N(alkyl)-, —O—, or —CH 2 —.
111 . The compound of claim 109 , wherein R 22a is substituted phenyl or substituted benzyl.
112 . The compound of claim 109 , wherein R 22a is
113 . The compound of claim 109 , wherein R 22b is hydrogen or methyl.
114 . The compound of claim 100 , wherein A is
115 . The compound of claim 100 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts, hydrates, enantiomers and stereoisomers thereof.
116 . A pharmaceutical composition comprising a compound of claim 100 and a pharmaceutically acceptable diluent or carrier.
117 . A kit or packaged pharmaceutical comprising a compound of claim 100 and instructions for use thereof.
118 . A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 100 .
119 . A compound selected from the group consisting of:
and pharmaceutically acceptable salts, hydrates, enantiomers and stereoisomers thereof.Join the waitlist — get patent alerts
Track US2016068559A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.